IOVA ALERT: Securities Fraud Class Action Filed Against Iovance by Levi & Korsinsky

A securities fraud class action has been filed against Iovance Biotherapeutics, Inc. by Levi & Korsinsky. The deadline for interested parties to participate is on July 14, 2025. The class action centers around allegations of securities fraud and misleading statements made by the company. Levi & Korsinsky is urging shareholders who have suffered losses to contact them before the deadline.

The class action lawsuit alleges that Iovance Biotherapeutics, Inc. made false and misleading statements regarding the efficacy of its cancer treatment products. It is claimed that the company overstated the results of clinical trials and failed to disclose relevant information to its shareholders. These alleged actions led to inflated stock prices, which ultimately caused financial harm to investors when the truth was revealed.

Levi & Korsinsky is a well-known law firm specializing in securities litigation. They have a track record of successfully representing shareholders who have been affected by fraudulent practices in the market. The firm is committed to holding companies accountable for their actions and seeking justice for those who have suffered financial losses.

Shareholders of Iovance Biotherapeutics, Inc. who purchased stock between a certain period are eligible to participate in the class action lawsuit. It is essential for shareholders to act quickly and contact Levi & Korsinsky before the July 14, 2025, deadline to ensure their inclusion in the legal proceedings. By joining the lawsuit, shareholders have the opportunity to seek compensation for the losses they incurred as a result of the alleged securities fraud.

Investors should be cautious when considering where to put their money and conduct thorough research before making investment decisions. It is crucial to be aware of any potential risks associated with a company’s practices and disclosures. By staying informed and seeking legal recourse when necessary, shareholders can protect their interests and hold companies accountable for any wrongdoing.

The deadline for shareholders to participate in the securities fraud class action against Iovance Biotherapeutics, Inc. is fast approaching. Levi & Korsinsky is dedicated to representing the interests of shareholders who have been impacted by the alleged misconduct of the company. Investors who have suffered financial losses are encouraged to contact the law firm before the July 14, 2025, deadline to learn more about their legal options and seek potential compensation for their losses.